Combination of metformin and phenformin synergistically inhibits proliferation and hTERT expression in human breast cancer cells.

Davoud Jafari-Gharabaghlou, Younes Pilehvar‐Soltanahmadi, Mehdi Dadashpour, Ali Mota, Soheila Vafajouy-Jamshidi, Leila Faramarzi, Sara Rasouli, Nosratollah Zarghami

PubMed · 2018 · 59 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

OBJECTIVES: Breast cancer remains a global challenge, and further chemopreventive therapies are still immediately required. Emerging evidence has revealed the potent anti-cancer effects of biguanides, Metformin (MET) and phenformin (PHE). Thus, to explore an efficient chemopreventive strategy for breast cancer, the antiproliferative effects of the combination of MET and PHE against breast cancer cells were assessed. MATERIALS AND METHODS: Cytotoxicity of the drugs individually and in combination against T47D and MDA-MB-231 breast cancer cells were assessed using MTT assay and the median-effect method was used to analyze the precise nature of the interaction between MET and PHE. Besides, the expression levels of hTERT after 48 hr drug exposure were determined using qRT-PCR. RESULTS: <0.001). CONCLUSION: It is speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.speculated that the combination of MET and PHE may be a promising and convenient approach to improve the efficiency of breast cancer treatment.

References

35